BIOMAT Database Logo BIOMAT Database Logo

Central nervous system effects of high-dose cytosine arabinoside. 1987

R H Herzig, and G P Herzig, and S N Wolff, and J D Hines, and J W Fay, and G L Phillips

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002526 Cerebellar Diseases Diseases that affect the structure or function of the cerebellum. Cardinal manifestations of cerebellar dysfunction include dysmetria, GAIT ATAXIA, and MUSCLE HYPOTONIA. Cerebellar Dysfunction,Cerebellum Diseases,Cerebellar Disorders,Cerebellar Syndromes,Cerebellar Disease,Cerebellar Disorder,Cerebellar Dysfunctions,Cerebellar Syndrome,Cerebellum Disease,Disease, Cerebellar,Disease, Cerebellum,Disorder, Cerebellar,Dysfunction, Cerebellar,Syndrome, Cerebellar
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

R H Herzig, and G P Herzig, and S N Wolff, and J D Hines, and J W Fay, and G L Phillips
Central nervous system toxicity of high-dose cytosine arabinoside.
June 1985, Seminars in oncology,
R H Herzig, and G P Herzig, and S N Wolff, and J D Hines, and J W Fay, and G L Phillips
Central nervous system pharmacokinetics of high-dose cytosine arabinoside.
January 1985, Journal of neuro-oncology,
R H Herzig, and G P Herzig, and S N Wolff, and J D Hines, and J W Fay, and G L Phillips
Central nervous system toxicity of high-dose cytosine arabinoside.
January 1983, Medical and pediatric oncology,
R H Herzig, and G P Herzig, and S N Wolff, and J D Hines, and J W Fay, and G L Phillips
[High-dose cytosine arabinoside].
February 1985, Onkologie,
R H Herzig, and G P Herzig, and S N Wolff, and J D Hines, and J W Fay, and G L Phillips
Treatment of central nervous system leukemia with intrathecal cytosine arabinoside.
October 1973, Cancer,
R H Herzig, and G P Herzig, and S N Wolff, and J D Hines, and J W Fay, and G L Phillips
Pharmacokinetics and metabolism of cytosine arabinoside in the central nervous system.
July 1982, The Journal of pharmacology and experimental therapeutics,
R H Herzig, and G P Herzig, and S N Wolff, and J D Hines, and J W Fay, and G L Phillips
Neurotoxicity of high-dose cytosine arabinoside.
January 1985, Progress in experimental tumor research,
R H Herzig, and G P Herzig, and S N Wolff, and J D Hines, and J W Fay, and G L Phillips
High-dose cytosine arabinoside-associated pancreatitis.
October 1985, Cancer,
R H Herzig, and G P Herzig, and S N Wolff, and J D Hines, and J W Fay, and G L Phillips
Cerebellar toxicity following high-dose cytosine arabinoside.
May 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
R H Herzig, and G P Herzig, and S N Wolff, and J D Hines, and J W Fay, and G L Phillips
Pseudotumour cerebri following high-dose cytosine arabinoside.
April 1992, British journal of haematology,
Copied contents to your clipboard!